PB2607: OBESITY IMPAIRS RESPONSE TO FIRST-LINE HIGH-DOSE DEXAMETHASONE IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA.

PB2607: OBESITY IMPAIRS RESPONSE TO FIRST-LINE HIGH-DOSE DEXAMETHASONE IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA.

Bibliographic Details
Main Authors:	Gege Feng, Xiaoyu Zhang, Qiang Liu, Shuwen Wang, Jun Peng
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000977116.42601.f3

Similar Items

PB2307: A MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ROMIPLOSTIM PLUS DEXAMETHASONE VS DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED PRIMARY IMMUNE THROMBOCYTOPENIA
by: M. E. Mingot Castellano, et al.
Published: (2022-06-01)

Efficacy of high-dose methylprednisolone as a first-line therapy in adult patients with immune thrombocytopenia
by: Kaniye Aydın, et al.
Published: (2022-06-01)

First-line Therapy for Immune Thrombocytopenia: Time for Change
by: Roger E. G. Schutgens
Published: (2022-10-01)

First line treatment of adult patients with primary immune thrombocytopenia: a real-world study
by: Liang Wang, et al.
Published: (2020-01-01)

PB2315: EFFICACY AND SAFETY OF TWO DIFFERENT LOW-DOSE RITUXIMAB REGIMENS FOR CHINESE CHILDREN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA
by: X. Zhu
Published: (2022-06-01)

Comparison of dexamethasone and Anti-D Immune globulin for immune thrombocytopenia purpura in children
by: Abdollah Banihashem, et al.
Published: (2014-04-01)

The association between platelet glycoprotein-specific antibodies and response to short-term high-dose dexamethasone with prednisone maintenance treatment in adult patients with primary immune thrombocytopenia
by: Yan-Qiu Hou, et al.
Published: (2022-12-01)

Efficacy and safety of bortezomib plus dexamethasone in patients with refractory primary immune thrombocytopenia: A single-center study
by: Li-na Liu, et al.
Published: (2023-12-01)

PB2306: RELAPSE OF IMMUNE THROMBOCYTOPENIA AND MYOCARDITIS
by: F. Kapsouli, et al.
Published: (2022-06-01)

Relationships of platelet glycoprotein specific antibody with therapeutic efficacy of short-term high-dose dexamethasone and bleeding score in the newly diagnosed adult patients with primary immune thrombocytopenia
by: Mengting Song, et al.
Published: (2023-12-01)

Anti-GPIb/IX autoantibodies are associated with poor response to dexamethasone combined with rituximab therapy in primary immune thrombocytopenia patients
by: Bingjie Ding, et al.
Published: (2023-12-01)

Decreased cyclooxygenase-2 associated with impaired megakaryopoiesis and thrombopoiesis in primary immune thrombocytopenia
by: Xibing Zhuang, et al.
Published: (2023-08-01)

Primary immune thrombocytopenia in children
by: Agnieszka Książek, et al.
Published: (2021-03-01)

Evaluation of treatment plan by three-period pulses of high-dose dexamethasone among patients with primary immune thrombocytopenia on platelet count response and adverse events: A randomized Clinical trial
by: Alireza Sadeghi, et al.
Published: (2020-01-01)

Second-line and beyond: treatment options for primary persistent and chronic immune thrombocytopenia
by: Samuel Deshayes, et al.
Published: (2020-04-01)

PB2636: VAYHIT1: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF IANALUMAB VERSUS PLACEBO IN ADDITION TO FIRST-LINE CORTICOSTEROIDS IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
by: Nichola Cooper, et al.
Published: (2023-08-01)

PB2685: QUALITY OF LIFE IN INDIAN ADULTS WITH IMMUNE THROMBOCYTOPENIA
by: Vivek Bhat, et al.
Published: (2023-08-01)

Therapeutic Outcomes of High Dose-Dexamethasone versus Prednisolone + Azathioprine, Rituximab, Eltrombopag, and Romiplostim Strategies in Persistent, Chronic, Refractory, and Relapsed Immune Thrombocytopenia Patients
by: Eman Mostafa Hamed, et al.
Published: (2023-08-01)

PB2316: EFFICACY AND SAFETY OF ELTROMBOPAG IN PEDIATRIC PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA AND ITS EFFECT ON CELLULAR IMMUNE FUNCTION
by: ?. 吴
Published: (2022-06-01)

PB2623: AVATROMBOPAG FOR THE TREATMENT OF CHILDREN WITH PERSISTENT AND CHRONIC IMMUNE THROMBOCYTOPENIA
by: Qi An, et al.
Published: (2023-08-01)

PB2637: OUR EXPERIENCE WITH AVATROMBOPAG TREATMENT IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
by: Libor Cervinek
Published: (2023-08-01)

Factors Associated with Thrombosis in Primary Immune Thrombocytopenia
by: YANG Shuo, WANG Yong, CHEN Shuxia, ZHAO Mingfeng
Published: (2022-02-01)

Immune Thrombocytopenia in Antiphospholipid Syndrome: Is It Primary or Secondary?
by: Riccardo Tomasello, et al.
Published: (2021-09-01)

Efgartigimod alfa for the treatment of primary immune thrombocytopenia
by: Catherine Broome
Published: (2023-05-01)

PB2625: VAYHIT2: A RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF IANALUMAB VS PLACEBO IN ADDITION TO ELTROMBOPAG IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) WHO FAILED FIRST-LINE STEROID TREATMENT
by: Francesco Zaja, et al.
Published: (2023-08-01)

PB2606: REAL-WORLD EXPERIENCE OF HETROMBOPAG IN RELAPSE AND REFRACTORY IMMUNE THROMBOCYTOPENIA
by: Yimei Feng, et al.
Published: (2023-08-01)

Comparison of antiplatelet antibody profiles between hepatitis C virus-associated immune thrombocytopenia and primary immune thrombocytopenia
by: Cih-En Huang, et al.
Published: (2021-11-01)

Case report: Ruxolitinib plus dexamethasone as first-line therapy in haemophagocytic lymphohistiocytosis
by: Lin Zhao, et al.
Published: (2023-03-01)

Scoping Review on Epigenetic Mechanisms in Primary Immune Thrombocytopenia
by: Jian Hong Tan, et al.
Published: (2023-02-01)

Primary Immune Thrombocytopenia in Pregnancy: Pathology, Diagnosis, and Management
by: Jiaying Liu, et al.
Published: (2023-12-01)

How we treat primary immune thrombocytopenia in adults
by: Xin-guang Liu, et al.
Published: (2023-01-01)

PB2301: PEDIATRIC IMMUNE THROMBOCYTOPENIA; A GLANCE AT PATIENTS AND CURRENT THERAPEUTIC CHALLENGES
by: M. Al-Jadiry, et al.
Published: (2022-06-01)

PB2631: CLINICAL FEATURES, TREATMENTS AND OUTCOMES OF PRIMARY IMMUNE THROMBOCYTOPENIA IN ADULTS: A SINGLE CENTER RETROSPECTIVE STUDY FROM TUNISIA.
by: Yasmine Bnouni, et al.
Published: (2023-08-01)

Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia
by: Dickinson, M, et al.
Published: (2018)

PB2303: THROMBOCYTOPENIA IN COVID-19 PATIENTS ON ECMO SUPPORT
by: C. Jones, et al.
Published: (2022-06-01)

Choriocarcinoma cell line response to dexamethasone
by: Bojić-Trbojević Žanka, et al.
Published: (2010-01-01)

Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management
by: Anurag Singh, et al.
Published: (2021-02-01)

Emergency Splenectomy in a patient with primary immune thrombocytopenia and hemoperitoneum
by: Liermis Michael Dita Salabert, et al.
Published: (2013-08-01)

Clinical Presentation and Therapy of Primary Immune Thrombocytopenia Resistant to Splenectomy
by: Aleksandar Kara-Jovanović, et al.
Published: (2020-04-01)

Gut microbiota alterations in children and their relationship with primary immune thrombocytopenia
by: Xiangyu Li, et al.
Published: (2023-06-01)